|
|
Article: HemoBioTech's Human Blood Substitute, HemoTech, Highlighted in Scientific American Online.
- Article from:
- Business Wire
- Article date:
- November 20, 2007
CopyrightCOPYRIGHT 2007 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
DALLAS -- HemoBioTech, Inc.'s (OTCBB: HMBT, http://www.hemobiotech.com), HemoTech, potentially the first viable substitute for human blood, was highlighted in the November 13, 2007 online edition of Scientific American as the lead story in its news section.
The full text of the article, entitled "New Blood Substitutes Promise Relief For Sagging Blood Banks," notes that HemoTech "not only suppresses hemoglobin's inherent toxicity, but also serves to improve blood flow and even spur the creation of new red blood cells." Other products using hemoglobin or perfluorocarbon compounds as blood substitutes have shown toxicity problems in their clinical trials. The ...
Related newspaper, magazine, and journal articles:
|
|
Article: HemoBioTech, Inc. Engages Regulus for FDA Services; ...
PR Newswire;
December 21, 2005 ;
700+ words
... ... 21 /PRNewswire-FirstCall/ -- HemoBioTech, Inc. (BULLETIN BOARD: HMBT) announced ... working with Regulus on their services for HemoBioTech. An initial foreign clinical study ... Chairman and Chief Executive Officer of HemoBioTech. Dr. Bollon further stated, "Our ...
|
|